RARE-32. Phase 0 and feasibility single-institution clinical trial of intravenous tocilizumab for adamantinomatous craniopharyngioma

BACKGROUND: Adamantinomatous craniopharyngioma (ACP) is a devastating skull-base tumor believed to derive from epithelial remnants of the primordial craniopharyngeal duct (Rathke’s pouch), which gives rise to the anterior pituitary gland. ACP lacks medical antitumor therapies. Current standard thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorris, Kathleen, Mettetal, Ashley, Dahl, Nathan, Hemenway, Molly, Winzent-Oonk, Shelby, Prince, Eric, Vijmasi, Trinka, McWilliams, Jennifer, Jordan, Kimberly, Mirsky, David, Hoffman, Lindsey, Hankinson, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Craniopharyngioma and Rare Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165090/
http://dx.doi.org/10.1093/neuonc/noac079.057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165090/
http://dx.doi.org/10.1093/neuonc/noac079.057

Ejemplares similares